Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and... see more

Bullboard (TSX:ONC)

View:
Comment by Buckhenryon Dec 02, 2024 5:16pm

RE:RE:Weekend update , hello all

We are sure lucky that sp does not matter. Wonder how nasdaq feels about that???
Post by spesestsemperon Dec 02, 2024 2:17pm

master protocol

I would hope when they make the announcement in the next little bit about the master protocol ,they take the time and explain what it actually means . What is the scope and depth of it ? Does it mean ...more  
Post by spesestsemperon Dec 02, 2024 1:10pm

pr piece

Biotech Advances Drive Cancer Research as Global Rates Continue Upward Trend Once the master protocol is finalized with the Global Coalition for Adaptive Research (GCAR), Oncolytics  ...more  
Comment by Quentin30on Dec 02, 2024 1:09pm

RE:Weekend update , hello all

Interesting tome Canaduh... the PC trial could indeed lead to a partnership,... but it's worth remembering that the oft touted Phase III ready mBC co-therapy, INCLUDES Chemo... and It is likely ...more  
Comment by Noteableon Dec 01, 2024 6:46pm

RE:RE:RE:RE:RE:RE:RE:RE:RE:Biotech industry readies for " Pharma M&A Spree"

Ken Keller, President and CEO of Daiichi Sankyo, Inc. provides an in-depth look into the company's transformation from a cardiovascular-focused organization to a leader in oncology. The ...more  
Comment by Buckhenryon Dec 01, 2024 5:08pm

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:How does Accelerated Approval work

I'm not sure why someone would come to this site and get all emotional and tell their life medical history. THIS IS NOT THE PLACE FOR THAT. I would not want to disclose any personal info here ...more  
Comment by Buckhenryon Dec 01, 2024 4:26pm

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:How does Accelerated Approval work

Just because canuckcluck etal has more followers only proves my point of how gullible blind folks are. All anyone has to do is look at the 5 year chart to prove my point. Figures font lie but liars ...more  
Comment by Noteableon Dec 01, 2024 3:47pm

RE:Roche inks $1.5B Poseida buyout

Leerink Partners is the sole book-runner in Replimmune's US$140 million follow-on raise. https://leerink.com/transactions/
Post by canadafanon Dec 01, 2024 2:39pm

Weekend update , hello all

I know there is a core group of visitors to this site. Many resd, few post. FYI, Mr. Buck. My posts get on average 5x to 10x if not more, than your reads. why woukd that be? Talking about telling ...more  
Comment by Noteableon Dec 01, 2024 1:26pm

RE:RE:RE:RE:RE:RE:RE:RE:Biotech industry readies for " Pharma M&A Spree"

Some bigger deals have been completed this year but none were instances in which a pharma group was buying a biotech to get hold of promising drugs.  A tough antitrust environment under Lina ...more  
Comment by Noteableon Dec 01, 2024 12:32pm

RE:RE:RE:RE:RE:RE:RE:Biotech industry readies for " Pharma M&A Spree"

M&A tends to pick up as company’s approach big Loss of Exclusivity (LOE) events. For Merck, they’re facing a $30B LOE in 2028 with Keytruda and have made big bets on Acceleron ($11.5B ...more  
Comment by Buckhenryon Nov 29, 2024 7:36pm

RE:RE:RE:RE:RE:RE:RE:RE:RE:How does Accelerated Approval work

We have not seen close to $5 since December 2019... that should speak volumes and tells the true story...  not the nake believe world of the forever pumpers. 
Comment by Noteableon Nov 29, 2024 5:59pm

RE:RE:RE:RE:RE:RE:What's with Morgan Stanley Canada hitting the bid with 100

Recent Trades - Last 10 of 356   Time ET Ex Price Change Volume Buyer Seller Markers 16:00:00 ...more  
Comment by Noteableon Nov 29, 2024 5:54pm

RE:RE:RE:RE:RE:What's with Morgan Stanley Canada hitting the bid with 100

"  single target of Non-muscle invasive bladder cancer (NMIBC) "
Comment by Noteableon Nov 29, 2024 5:52pm

RE:RE:RE:RE:What's with Morgan Stanley Canada hitting the bid with 100

The OV company CG Oncology with a single target of Non-muscle invasic bladder cancer (NMIBC) has a market ap of US$2.35 Billion at today's close. https://cgoncology.com/pipeline/
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities